Since the introduction of the HPV vaccine, questions have been asked about its efficacy in preventing cancer linked
with HPV. Concerns about the HPV vaccine safety profile have also been raised. This paper highlights the rapidly
growing body of evidence (including clinical trials and post-marketing surveillance) illustrating both the safety of
the HPV vaccine, through a detailed investigation of reported adverse events, and its efficacy in reducing both HPV
infections rates and the resulting drop in cervical lesions, which have been demonstrated to be good predictors of
cervical cancer risk.